TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30792143

Group type: COMPARATOR
Intervention: 2 g PS
Number of subjects: 72

Group type: COMPARATOR
Intervention: 3 g OBG
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2 g PS and 3 g OBG
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 72
Study: 30221776

Group type: EXPERIMENTAL
Intervention: NIR t‐PBM
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 20
Study: 28640772

Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (25 ml of an 18% CHO solution)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-rinse control condition
Number of subjects: 12
Study: 25880414

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone health coaching
Number of subjects: 556

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 556
Study: 23865053

Group type: EXPERIMENTAL
Intervention: Fluorometholone/tetrahydrozoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 21135733

Group type: EXPERIMENTAL
Intervention: Ictal SPECT
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-SPECT
Number of subjects: 240
Study: 19170716

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg) for 16 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hirsute patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 30
Study: 17309907

Group type: EXPERIMENTAL
Intervention: Disease management programme delivered by specialist nurses trained in the management of patients with CHD and CHF
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Usual care delivered by the primary healthcare team
Number of subjects: 1316
Study: 14996882

Group type: EXPERIMENTAL
Intervention: Handheld computer documentation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional paper documentation
Number of subjects: 78
Study: 11321192

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (oGA) for 2,433 +/- 59 days
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo (oPBO) followed by glatiramer acetate for 1,476 +/- 63 days
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both groups (oPBO and oGA)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (oGA)
Number of subjects: 208
Study: 9396960

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7648784

Group type: EXPERIMENTAL
Intervention: Insulin modified FSIVGTT (insulin infusion at 4 mUkg‐1.min‐1 from time 20 to 25 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard FSIVGTT (glucose infusion of 0.3 g/kg from time 0 to 2 min)
Number of subjects: 10
Study: 2953752

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate administered daily for 4 weeks followed by concomitant hMG administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG) only
Number of subjects: 0
Study: 31251544

Group type: EXPERIMENTAL
Intervention: Low-density MFU-V treatments
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-density MFU-V treatments
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-density MFU-V treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Self-assessment questionnaires
Number of subjects: 91
Study: 29960200

Group type: EXPERIMENTAL
Intervention: Vaginal diazepam plus transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo plus transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 42
Study: 27068760

Group type: EXPERIMENTAL
Intervention: Anti-malarial treatment (specific dosage and duration not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improving women's knowledge of malaria in pregnancy
Number of subjects: 0
Study: 24558011

Group type: EXPERIMENTAL
Intervention: Hot drink (paracetamol)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tablet (paracetamol)
Number of subjects: 25
Study: 22721545

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1 g loading dose followed by 1 g maintenance dose over 8 hours
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study: 19541477

Group type: EXPERIMENTAL
Intervention: Symptoms of sexual dysfunction (measured by self-completed questionnaire)
Number of subjects: 8924
Study: 17227744

Group type: EXPERIMENTAL
Intervention: Homeopathic combination medication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15943961

Group type: EXPERIMENTAL
Intervention: Oxytrex bid (twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytrex bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone qid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12213107

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg day(-1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9796240

Group type: EXPERIMENTAL
Intervention: Integrated epidural/general anaesthesia
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Prophylactic volume preload
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Epidural clonidine
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Prophylactic atropine before epidural block
Number of subjects: 1200
Study: 7704460

Group type: EXPERIMENTAL
Intervention: Slow‐acting anti‐rheumatic drugs (SAARD)
Number of subjects: 115
Study: 2696292

Group type: EXPERIMENTAL
Intervention: 3% Felbinac gel (1 or 2 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral Fenbufen (300 mg thrice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical administration (Felbinac gel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin tissue concentrations after topical administration
Number of subjects: 30
Study: 773080

Group type: EXPERIMENTAL
Intervention: CB 154 (2-bromo-alpha-ergocryptine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Madopar (L-Dopa + benserazid)
Number of subjects: 20
Study: 30779528

Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation
Number of subjects: 401

Group type: COMPARATOR
Intervention: No ventilation
Number of subjects: 401
Study: 28120127

Group type: EXPERIMENTAL
Intervention: ONO-8539 (450 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25644589

Group type: EXPERIMENTAL
Intervention: Drug treatment during follow-up
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Income from sources other than sex work
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Police interactions
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Healthcare access
Number of subjects: 467
Study: 24702710

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted inactivated trivalent split-virion influenza vaccine (AS03-TIV)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (TIV)
Number of subjects: 595
Study: 22348696

Group type: EXPERIMENTAL
Intervention: SRP plus 1.2-mg SMV
Number of subjects: 72

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 72
Study: 19352587

Group type: EXPERIMENTAL
Intervention: GI + PP
Number of subjects: 76

Group type: COMPARATOR
Intervention: GI
Number of subjects: 76
Study: 18069280

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (SCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tandem autologous SCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous SCT followed by reduced-intensity conditioning allogeneic transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs including thalidomide, lenalidomide, or bortezomib in combination with SCT
Number of subjects: 0
Study: 15098135

Group type: EXPERIMENTAL
Intervention: Treated patients (vitreo‐retinal surgery, brachytherapy, proton beam radiation)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 140
Study: 17240934

Group type: EXPERIMENTAL
Intervention: Rolly Brush
Number of subjects: 0
Study: 10565800

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 30
Study: 9308335

Group type: EXPERIMENTAL
Intervention: Treatment for epilepsy
Number of subjects: 347
Study: 1863725

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 27
Study: 6870066

Group type: EXPERIMENTAL
Intervention: Vasodilator therapy (hydralazine or nifedipine) for Group I; nitroprusside followed by minoxidil or hydralazine for Group II.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control right heart catheterization for both groups.
Number of subjects: 35
Study: 31802198

Group type: EXPERIMENTAL
Intervention: Absorbable collagen biomembrane
Number of subjects: 100
Study: 31536935

Group type: EXPERIMENTAL
Intervention: Deltamethrin-impregnated dog collars (4%)
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Control area (no intervention)
Number of subjects: 1609
Study: 30372403

Group type: EXPERIMENTAL
Intervention: Research interest
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Physician-scientist decline and shortage
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Curriculum issues
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Skills (motivation and self-efficacy)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Research needs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Socioeconomic and cultural issues
Number of subjects: 26
Study: 26829094

Group type: COMPARATOR
Intervention: Whole-body vibration training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Whole-body vibration plus task-related training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 24794451

Group type: EXPERIMENTAL
Intervention: IPP 20mmHg (P20 group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: IPP 12mmHg (P12 group)
Number of subjects: 67
Study: 23146637

Group type: EXPERIMENTAL
Intervention: Tapered titanium posts (TPs)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tapered glass fiber-reinforced epoxy resin posts (GFREPs)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Both post materials (GFREPs and TPs)
Number of subjects: 91
Study: 21029429

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 600 mg thrice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18410211

Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (SAAF)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control families
Number of subjects: 167
Study: 15813357

Group type: COMPARATOR
Intervention: No treatment after the first seizure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rectal diazepam at seizure onset
Number of subjects: 30
Study: 12029546

Group type: EXPERIMENTAL
Intervention: Gated myocardial perfusion tomography (gMPT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Gated blood pool tomography (gBPT)
Number of subjects: 37
Study: 10489005

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 135
Study: 9545903

Group type: EXPERIMENTAL
Intervention: Compomer (Dyract)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resin composite (Pekafill)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RM GIC) (Fuji II LC)
Number of subjects: 50
Study: 1916649

Group type: EXPERIMENTAL
Intervention: met‐hGH (0.08 mg/kg desirable body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (bacteriostatic water diluent)
Number of subjects: 12
Study: 31792940

Group type: EXPERIMENTAL
Intervention: ADRD screening using the Memory Impairment Screen or the Mini-Cog
Number of subjects: 4005

Group type: EXPERIMENTAL
Intervention: ADRD screening
Number of subjects: 4005

Group type: COMPARATOR
Intervention: Control group (no ADRD screening)
Number of subjects: 4005
Study: 31169794

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 3 × 5 min occlusion 220 mm Hg/reperfusion 0 mm Hg, bilaterally on thighs
Number of subjects: 13

Group type: COMPARATOR
Intervention: SHAM - 20 mm Hg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 13
Study: 29245223

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25228126

Group type: EXPERIMENTAL
Intervention: 10 mg of prednisone daily for 2 years
Number of subjects: 0
Study: 23230115

Group type: EXPERIMENTAL
Intervention: High nitrogen (HN; CON plus urea supplement)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High nitrogen and sulfur (HNS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High sulfur (HS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON; 13.4% CP and 0.17% S)
Number of subjects: 20
Study: 21261241

Group type: EXPERIMENTAL
Intervention: IO myectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: IO recession
Number of subjects: 50
Study: 19913145

Group type: EXPERIMENTAL
Intervention: ETG-releasing implant
Number of subjects: 40

Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 40
Study: 16762627

Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg daily
Number of subjects: 286

Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 286
Study: 14973334

Group type: EXPERIMENTAL
Intervention: Flexion of the distal interphalangeal joints of individual fingers
Number of subjects: 8
Study: 11722408

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + Colistin (CIP + COL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neomycin + Colistin (NEO + COL)
Number of subjects: 64
Study: 9137175

Group type: EXPERIMENTAL
Intervention: Percutaneous laser nucleolysis with a carbon dioxide laser
Number of subjects: 50
Study: 7956657

Group type: EXPERIMENTAL
Intervention: ThinPrep preparation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Conventional Pap smear
Number of subjects: 1000
Study: 3604619

Group type: EXPERIMENTAL
Intervention: 5,000 IU heparin and 0.5 mg dihydroergotamine injected subcutaneously twice daily
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 194
Study: 31286727

Group type: EXPERIMENTAL
Intervention: Huoxue Sanfeng and Tiaohe Ganpi acupuncture
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nifedipin (Control)
Number of subjects: 76
Study: 27545858

Group type: COMPARATOR
Intervention: NTP‐CE (new topical panthenol‐containing emollient)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control areas
Number of subjects: 109
Study: 25092537

Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 23796707

Group type: EXPERIMENTAL
Intervention: 3-month multidisciplinary intervention
Number of subjects: 21
Study: 21774708

Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 331

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 331
Study: 19353407

Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment (indapamide 1.5 mg sustained release +/‐2‐4 mg perindopril)
Number of subjects: 3845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3845
Study: 16310299

Group type: EXPERIMENTAL
Intervention: Repetitive asymmetric lifts by novice handlers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repetitive asymmetric lifts by experienced handlers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repetitive asymmetric lifts at unaccustomed lift frequencies and weights
Number of subjects: 24
Study: 12717213

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg per dose every 14 days for five doses (group I, n=107)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg per dose every 14 days for two doses (group II, n=112)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No antibody induction (group III, n=78)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg per dose every 14 days for five doses (group I)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg per dose every 14 days for two doses (group II)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No antibody induction (group III)
Number of subjects: 297
Study: 11117873

Group type: EXPERIMENTAL
Intervention: TAK-044
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 9166992

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 0
Study: 8419001

Group type: EXPERIMENTAL
Intervention: Synthetic 28-amino acid alpha-human ANP (0.1 micrograms/kg per minute)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 14
Study: 3706427

Group type: EXPERIMENTAL
Intervention: Fasted state (50 gm, 1-hour plasma glucose screening test)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fed state (50 gm, 1-hour plasma glucose screening test after a standard 600 kcal meal)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fed state (50 gm, 1-hour plasma glucose screening test)
Number of subjects: 70
Study: 30957487

Group type: EXPERIMENTAL
Intervention: Single Sampling (SS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Random Sampling (RS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Line Sampling (LS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All sampling strategies (SS, RS, LS)
Number of subjects: 10
Study: 28673328

Group type: EXPERIMENTAL
Intervention: Individualized pedometer-based walking program with weekly step goals, behavioral face-to-face sessions with a physician, and regular telephone calls with a research nurse for 6 months.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Individualized pedometer-based walking program
Number of subjects: 200
Study: 25879592

Group type: EXPERIMENTAL
Intervention: PAV₁₅₀
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NAVA₁₅₀
Number of subjects: 16

Group type: COMPARATOR
Intervention: PSV₁₅₀
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAV₁₀₀
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NAVA₁₀₀
Number of subjects: 16

Group type: COMPARATOR
Intervention: PSV₁₀₀
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAV
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAV and NAVA
Number of subjects: 16
Study: 24286472

Group type: EXPERIMENTAL
Intervention: Discontinuation of adalimumab (ADA)
Number of subjects: 50
Study: 21931037

Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 92
Study: 19186727

Group type: EXPERIMENTAL
Intervention: Acupoint stimulating therapy
Number of subjects: 3697
Study: 16426990

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study: 15086180

Group type: EXPERIMENTAL
Intervention: Music therapy during colonoscopy, n=15
Number of subjects: 29

Group type: COMPARATOR
Intervention: No music during colonoscopy, n=14
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: No music
Number of subjects: 29
Study: 11500289

Group type: EXPERIMENTAL
Intervention: Teaching by physical examination teaching associates (PETAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional faculty‐taught course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of using PETAs
Number of subjects: 0
Study: 9731580

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN) 3 MU three times a week starting within 2 weeks after transplantation for 1 year
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (no IFN)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: HCV RNA level > 100 x 10(5) Eq/mL at 1 month after transplantation
Number of subjects: 86
Study: 7977894

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 62
Study: 2807006

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus twice-weekly cis-platinum (group III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus weekly cis-platinum (group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy only (group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cis-platinum (groups II and III)
Number of subjects: 0
Study: 808849

Group type: EXPERIMENTAL
Intervention: Sterile plastic‐tent isolators with laminar air flow (Life Islands) and whole-body decontamination
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reverse isolation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions in group A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Life Islands for patients with agranulocytosis of varying origin (group C)
Number of subjects: 28
Study: 29701041

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with femoral nerve block
Number of subjects: 60
Study: 26397982

Group type: EXPERIMENTAL
Intervention: Tryton dedicated side branch stent
Number of subjects: 289

Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 289
Study: 26198562

Group type: EXPERIMENTAL
Intervention: Health Connect system (telemonitoring and virtual provider appointments)
Number of subjects: 0
Study: 23073143

Group type: EXPERIMENTAL
Intervention: 100-mg sarpogrelate IR 3 times at a 6-h interval
Number of subjects: 36

Group type: COMPARATOR
Intervention: 300-mg sarpogrelate CR once
Number of subjects: 36

Group type: COMPARATOR
Intervention: CR formulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IR formulation
Number of subjects: 36
Study: 20624624

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 7 days before surgery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg for 7 days before surgery
Number of subjects: 104